Daniel Sinclair @_DanielSinclair Building for young people. Not reading @danielsunread. Lurking behind likes and thinking about social media, communication, & China. May. 24, 2019 1 min read

Very excited to see the gene therapy flood gates opening; this is now the 2nd therapy approved by the FDA, and many more are on the way.  https://www.statnews.com/2019/05/24/hold-novartis-zolgensma-approval/ 

On a 30 to 70 year horizon, the gene therapy market feels fairly ephemeral. Germline edits and IVF sequencing will be drastically more cost-effective as primary treatment. As our genome understanding increases, the gene therapy market will ultimately peak and then rapidly decline

Societal pressure & norm will ultimately push towards germline edits. But there's other factors: fertility globally is plummeting, and we may have no choice. "[Concentration] declined more than 50% from 1973 to 2011... total counts were down by almost 60%"  https://www.theatlantic.com/family/archive/2018/10/sperm-counts-continue-to-fall/572794/ 

You can follow @_DanielSinclair.


Tip: mention @threader_app on a Twitter thread with the keyword “compile” to get a link to it.

Enjoy Threader? Sign up.

Threader is an independent project created by only two developers. The site gets 500,000+ visits a month and our iOS Twitter client was featured as an App of the Day by Apple. Running this space is expensive and time consuming. If you find Threader useful, please consider supporting us to make it a sustainable project.